Cogent Biosciences (COGT) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
9 Jun, 2026Opening remarks and agenda
The meeting was called to order and chaired by the President and CEO, with introductions of the board, management, and external advisors.
The agenda and rules of conduct were outlined, and participants were reminded of voting procedures.
Board and executive committee updates
The board of directors and executive management team were introduced, including the CFO and chief legal officer.
Shareholder proposals
Three proposals were presented: election of Class II directors, ratification of the independent auditor, and advisory approval of executive compensation.
Partial view of Summaries dataset, powered by Quartr API
Latest events from Cogent Biosciences
- Three FDA decisions ahead; launch infrastructure is ready for near-term approvals.COGT
UBS Global Biopharma Conference 2026 - Bezuclastinib nears U.S. decisions with launch readiness and pipeline expansion underway.COGT
3rd Annual Guggenheim Healthcare Innovation Conference - Three bezuclastinib FDA decisions loom as $791.1M in liquidity supports launch preparations.COGT
Q3 2026 - Three NDAs pending FDA review, strong trial results, and cash runway into late 2028.COGT
Q2 2026 - Pivotal trial readouts for bezuclastinib in rare diseases and GIST expected in 2025.COGT
Guggenheim SMID Cap Biotech Conference - Bezuclastinib plus sunitinib delivers breakthrough efficacy in GIST, with rapid adoption anticipated.COGT
Jefferies Global Healthcare Conference 2026 - Bezuclastinib's pivotal trial wins set up a transformative 2026 launch and long-term market leadership.COGT
44th Annual J.P. Morgan Healthcare Conference - Bezuclastinib delivered robust symptom and biomarker improvements with good tolerability in non-advanced SM.COGT
Study Result - Pivotal trial readouts for Bezuclastinib in SM and GIST expected in 2025, with strong market potential.COGT
Piper Sandler 36th Annual Healthcare Conference